Latest Solu Therapeutics News & Updates

See the latest news and media coverage for Solu. We track all announcements, press releases, and industry mentions in real time, all in one place.

Solu Therapeutics (Solu)

Clinical-stage biotechnology company

solutherapeutics.com

Headquarters: Boston , United States
Company type: Private company
Number of employees: 2–25
Industry: Pharmaceuticals

Last updated Today

Latest news about Solu Therapeutics (Solu)

In short: Solu secured $41M in Series A funding and initiated Phase 1 clinical trials for its lead candidate STX-0712 to treat blood cancers.

Company announcements

June 22 Solu

Solu Therapeutics received FDA Fast Track designation.

The designation is for their lead CyTAC program targeting relapsed or refractory CMML.

May 27 Solu

Solu Therapeutics granted FDA Fast Track designation for STX-0712

The investigational therapy targets chronic myelomonocytic leukemia, an aggressive blood cancer with limited options.

9 April 2024 Solu

Solu Therapeutics closes $41M Series A and doses first patient

The funding supports clinical evaluation of STX-0712, a novel CCR2-CyTAC therapy for CMML and other hematologic malignancies.

11 September 2023 Solu

Solu Therapeutics appoints Philip Vickers as President and CEO

He succeeds co-founder David Donabedian and brings over 30 years of biopharma experience to lead development of CyTaC platform.

Media coverage

July 9 Business Wire

Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets

BOSTON--(BUSINESS WIRE)--Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, today announced the closing of an oversubscribed $31 million...

22 October 2025 BioWorld

Solu Therapeutics discovers Nav1.7 and Nav1.8 blockers for pain and more

Solu Therapeutics Inc. has identified heterobifunctional cotinine-containing compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers or sodium channel protein type...

9 April 2025 Yahoo Finance

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic ...

Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial...

1 August 2023 GEN

Solu Therapeutics Launches with $31 Million to Unlock Cell-Surface Targets

Six years ago, Brandon Turunen, PhD, answered a call from his employer, GSK, for proposals to develop new medicines. "They would oftentimes do calls for...

Never miss news about Solu

Track Solu and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.